Risk factors

Interest rate sensitivity and regulatory compliance dominate the risk disclosures. China revenue concentration dropped slightly from 35% to 34%. Global workforce expansion increased international geopolitical exposure.

Growth through the pending Stellar and recent American and Southwest bank acquisitions dominates risk disclosures. Cybersecurity threats and regulatory scrutiny on M&A compliance expanded.

Puma Biotechnology relies heavily on five major customers representing 74% of revenue, faces pricing pressures from healthcare reform and the One Big Beautiful Bill Act, and maintains an accumulated deficit of $1,283.8 million alongside $97.5 million in cash.

Pacira faces key risks in commercializing EXPAREL and ZILRETTA against generic and competitive pressures, managing manufacturing and supply chain vulnerabilities, and navigating stringent regulatory environments.

PureCycle added risks regarding its $363.7 million debt load, capital project execution hurdles, and the March 2026 expiration of share lock-up restrictions.

Interest-rate hedge exposure fell from eight swaps totaling $75.0 million to five totaling $45.0 million.

PJM supply shortages, driven by data centers, EVs and electrification, are raising capacity prices and customer supply rates.

PENN terminated its partnership with ESPN and rebranded its sportsbook to theScore Bet, resulting in an Interactive segment impairment.

OBBBA healthcare funding cuts could increase pricing controls and reduce demand, with CBO estimating 10 million more uninsured people.

Phathom Pharmaceuticals faces intense competition, reliance on VOQUEZNA commercial success, and strict ongoing regulatory requirements following product launches.

Piper Sandler updated economic outlooks for 2026, citing tariff uncertainty and changing investment banking activity levels from 2024 to 2025. Credit facility details and valuation estimate descriptions were updated with current operational references.

PJT Partners added specific focus on compliance with SEC, FINRA, and international regulatory net capital requirements and client policies. Cybersecurity risk disclosures expanded regarding client data processing and third-party networks. References to 2024 proxy statements and M&A volume conditions were updated to 2025 and broadened trade policies.